Eileen M O’Reilly
@eileenmoreilly
Oncologist MSK. TCD alum. Interests Pancreas, Hepatobiliary, GI Cancers, IRB Chair, Editor, Data & safety, Drug Development, Clinical trials, Alliance GI, NCTN
ID: 1128961551388557314
https://www.mskcc.org/cancer-care/doctors/eileen-o-reilly 16-05-2019 09:53:03
4,4K Tweet
5,5K Followers
2,2K Following
Please join us next Tuesday if you are interested in the field of oncology nutrition, cancer cachexia & systemic effects of diet in patients with #PancreaticCancer Neil Iyengar Cancer Cachexia Society Let's Win Pancreatic Cancer 💜 #PancChat
Join us in Miami, FL, US for #ISGIO! We’ll talk about #GI cancers #hepatobiliary cancers with clinical cases, lectures, and discussions! Tanios Bekaii-Saab, MD Eileen M O’Reilly Humanitas University Humanitas Milano PER
Huge congratulations to all my MD Anderson Cancer Center colleagues who are funded by CPRIT today. From high risk high reward awards (Wen Jiang MD, PhD) all the way to advanced spatial genomics core facility (Nicholas Navin) & everything in between! 🙌🏽 cprit.texas.gov/news-events/ar…
Join us in Hollywood, FL for PER’s #ISGIO! Learn about the latest advances in the field of #GIcancer research, and critical issues for the care of persons with GI cancer. Register now:bit.ly/4aR1Hrl #gotoPER #ISGIO Tanios Bekaii-Saab, MD Eileen M O’Reilly Humanitas Milano Humanitas University
🧬Mismatch repair in pancreatic cancer JAMA Oncology ✅Although it is rare, MSI should be tested in pancreatic cancer ✅Median IO duration: 27.7 months, DCR: 80% 👉doi:10.1001/jamaoncol.2024.3651 Catherine O’Connor Emily Harrold Wungki Park, MD MS Eileen M O’Reilly #cancer #Oncology #MedX
Catherine O’Connor JAMA Oncology Emily Harrold Eileen M O’Reilly Wungki Park, MD MS Fergus Keane It’s official, congratulations!!
Dr. Mark Lewis (Mark Lewis, MD, FASCO) and journalist Steve Doig explain how to judge whether the information about pancreatic cancer on the internet is from a reliable source. bit.ly/3MwvOdw
The study results suggest that orthogonal MS testing is critical to identify MSI-H in PC and patients with MSI-H PC should be treated with immune checkpoint blockade therapy. ja.ma/4gbePuZ Catherine O’Connor Eileen M O’Reilly
Catherine O’Connor JAMA Oncology Emily Harrold Eileen M O’Reilly Wungki Park, MD MS Fergus Keane Congrats!! This is so exciting and so well-deserved! JAMAOnc queen 👑
Roberta Horgan 🇮🇪 Catherine O’Connor JAMA Oncology Emily Harrold Eileen M O’Reilly Wungki Park, MD MS Fergus Keane I was about to tag you Roberta, but as always you're on the case xx
Catherine O’Connor JAMA Oncology Emily Harrold Eileen M O’Reilly Wungki Park, MD MS Congratulations Catherine O’Connor Emily Harrold Eileen M O’Reilly Zsofia Stadler delighted to see this in print!
Drew Moss JAMA Oncology Emily Harrold Eileen M O’Reilly Wungki Park, MD MS Fergus Keane Thanks for all your help 😊
JAMA Oncology Catherine O’Connor Eileen M O’Reilly Crucial findings on MSI-H in PC! I completely agree that orthogonal MS testing is vital for identification and immune checkpoint blockade therapy is the way to go for treatment.
Listen to an interview with Eileen M O’Reilly author of "Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer," with Vivek Subbiah, MD. Hosted on AMA Ed Hub™. ja.ma/4ebd9Q9
🚨Such a delight to host a JAMA Oncology PODCAST with the amazing Eileen M O’Reilly Memorial Sloan Kettering Cancer Center - we talk about how an #AI based classifier reclassified approximately 20% of cases with pancreatic cancer. 👉🏼#immunotherapy for patients with Lynch syndrome or somatic MSI-H PanCAN
